Tasso American Company believe they can find an alternative, the blood test process completely avoid the use of needles. The company has developed a ping-pong-sized blood sampling device, called HemoLink. Patients can self operate this device at home: Use only be placed on the skin of the arm or abdomen. Two minutes later, HemoLink blood sampling can be done automatically. Tasso founder at the University of Wisconsin study had conducted research on microfluidics, and research achievements in today HemoLink.

Currently, the company has been investment from the US Defense Advanced Research Projects Agency (DARPA) 300 million. HemoLink is a low one-time price of equipment, six injection molded plastic parts composition. Is a vacuum inside the device, so that a small amount of blood on it by capillary phenomenon (of a liquid in the inner small tubular object, due to differences in cohesion and adhesion, and eventually overcome gravity and rise of the phenomenon) is transferred to the device from the body of the vial in. Tasso company vice president, co-founder of Ben Casa Weng (Ben Casavant), said: "During the device to work, the surface tension of blood more than the force of gravity, so no matter how the user display device, blood will pass through capillary flow into the interior equipment. "HemoLink able to collect approximately 1.5cc of blood, which is sufficient for routine testing needs. After blood samples were collected, users only need to accept the analysis can be sent to the laboratory. Tasso said their target customers are those who require regular monitoring of blood glucose. "For patients who need regular blood cancer or to monitor chronic diseases, our products are suitable for them."

Tasso DARPA funds will be used to further improve the blood storage technology. DARPA hopes Tasso can develop technologies to maintain a stable blood to ensure that blood samples can be stored a week at 60 ° C environment. As a result, expensive blood cold chain transport links cease to exist. The company plans later this year to apply to the FDA, and in the years to HemoLink devices to market. If they eventually succeed, it will be two main benefits: on the one hand, hate needles no longer bear the pain of the needle patient; the other hand, the technology can reduce the cost of health care industry, and its ease of use, but also eliminates the people continue to go to the doctor before interrogation trouble.